Ostatnia aktualizacja :
14/12/2024
Lek przeciwhistaminowy H2   Ranitidine hydrochloride  
Injekcje
Roztwór doustny
Trwałość roztworów Trwałość w mieszaninie Czynnik wpływający na trwałość Zgodność Sposób podania Bibliografia pdf
   Struktura chemiczna  

Nazwa handlowa   Nazwa handlowa     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acloral Meksyk
Antak
Azantac
B-Alcerin
Coralen
Epadoren Grecja
Histac
Logat
Lumaren Grecja
Pep rani
Peptoran
Ptinolin Grecja
Ranic
Ranidil Włochy
Ranigast Polska
Ranisan
Ranitab Turcja
Ranital
Ranitic Niemcy
Ranitidin Niemcy
Rantag Niemcy
Rinavian Argentyna
Solvertyl
Stacer
Taural
Ulcuran Turcja
Ulsal Austria
Zantac Belgia, Dania, Grecja, Hiszpania, Holandia, Norwegia, Portugalia, Stany Zjednoczone Ameryki, Szwecja, Tajlandia, Turcja, Wielka Brytania, Włochy
Zantic Szwajcaria
Zydac Arabia Saudyjska
Zylium Brazylia
Bibliografia   Injekcje   Bibliografia : Ranitidine hydrochloride  
typ publikacja
3 Czasopismo Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
18 Czasopismo Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA.
Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 391-394.
36 Czasopismo Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
46 Czasopismo Nahata MC, Morosco RS, Fox JL.
Stability of ranitidine hydrochloride in water for injection in glass vials and plastic syringes.
Am J Health-Syst Pharm 1996 ; 53: 1588-1590.
47 Czasopismo Burm JP, Jhee SS, Chin A, Moon YSK.
Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration.
Am J Hosp Pharm 1994 ; 51: 1201-1204.
58 Czasopismo Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161.
78 Czasopismo Stewart JT, Warren FW, Johnson SM, Galante LJ.
Stability of ranitidine in intravenous admixtures stored frozen, refrigerated, and at room temperature.
Am J Hosp Pharm 1990 ; 47: 2043-2046.
81 Czasopismo Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Czasopismo Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Czasopismo Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Czasopismo Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Czasopismo Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Czasopismo Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
186 Czasopismo Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
187 Czasopismo Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS.
Stability of flumazenil with selected drugs in 5% dextrose injection.
Am J Hosp Pharm 1993 ; 50: 1907-1912.
198 Czasopismo Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
199 Czasopismo Hassan E, Leslie J, Martir-Herrero ML.
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 2143-2145.
208 Czasopismo Nolan PE, Hoyer GL, Ledoux JH, Fox JL.
Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 1997 ; 54: 1304-1306.
209 Czasopismo Williams MF, Hak LJ, Dukes G.
In vitro evaluation of the stability of raniditine hydrochloride in total parenteral nutrient mixtures.
Am J Hosp Pharm 1990 ; 47: 1574-1579.
210 Czasopismo Stewart JT, Warren FW, King AD.
Stability of ranitidine hydrochloride and seven medications.
Am J Hosp Pharm 1994 ; 51: 1802-1807.
213 Czasopismo Galante LJ, Stewart JT, Warren FW, Johnson SM, Duncan R.
Stability of ranitidine hydrochloride at dilute concentration in intravenous infusion fluids at room temperature.
Am J Hosp Pharm 1990 ; 47: 1580-1584.
214 Czasopismo Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ.
Stability of ranitidine hydrochloride with eight medications in intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 1606-1610.
235 Czasopismo Choi JS, Burm JP, Jhee SS, Chin A, Ulrich RW, Gill MA.
Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 2273-2276.
244 Czasopismo Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Czasopismo Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Czasopismo Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
266 Czasopismo Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288 Czasopismo Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962.
289 Czasopismo Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707.
299 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Czasopismo Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Czasopismo Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
314 Czasopismo Chiu MF, Schwartz ML.
Visual compatibility of injectable drugs used in the intensive care unit.
Am J Health-Syst Pharm 1997 ; 54: 64-65.
315 Czasopismo Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316 Czasopismo Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317 Czasopismo Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362.
334 Czasopismo Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Czasopismo Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Czasopismo Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Czasopismo Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
357 Czasopismo Cano SM, Montoro JB, Pastor C, Pou L, Sabin P.
Stability of ranitidine hydrochloride in total nutrient admixtures.
Am J Hosp Pharm 1988 ; 45: 1100-1102.
358 Czasopismo Lampasona V, Mullins RE, Parks RB.
Stability of ranitidine admixtures frozen and refrigerated in minibags.
Am J Hosp Pharm 1986 ; 43: 921-925.
359 Czasopismo Bullock LS, Parks RB, Lampasona V, Mullins RE.
Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions.
Am J Hosp Pharm 1985 ; 42: 2683-2687.
360 Czasopismo Inagaki K, Gill MA, Okamoto MP, Takagi J.
Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration.
Am J Hosp Pharm 1992 ; 49: 2769-2772.
384 Czasopismo Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632.
386 Czasopismo Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
396 Czasopismo Chilvers MR, Lysne JM.
Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications.
Am J Hosp Pharm 1989 ; 46: 2057-2058.
402 Czasopismo Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
404 Czasopismo Forman JK, Souney PF.
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Am J Hosp Pharm 1987 ; 44: 2298-2299.
406 Czasopismo Smythe MA, Patel MA, Gasloli RA.
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 819-820.
465 Czasopismo Wohlford JG, Wright JC, Wilson MR.
More information on the visual compatibility of hetastarch with injectable critical-care drugs.
Am J Hosp Pharm 1990 ; 47: 297-298.
472 Czasopismo Wohlford JG, Fowler MD.
Visual compatibility of hetastarch with injectable critical-care drugs.
Am J Hosp Pharm 1989 ; 46: 995-996.
479 Czasopismo Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
491 Czasopismo Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Czasopismo Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
660 Czasopismo Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
689 Czasopismo Walker SE, Kirby K.
Stability of ranitidine hydrochloride admixtures refrigerated in polyvinyl chloride minibags.
Can J Hosp Pharm 1988 ; 41: 105-108.
693 Czasopismo Das Gupta V, Parasrampuria J, Bethea C.
Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures.
J Clin Pharm Ther 1988 ; 13: 329-334.
813 Czasopismo Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68.
903 Czasopismo Inagaki K, Gill MA, Okamoto MP, Takagi J.
Chemical compatibility of cefmetazole sodium with ranitidine hydrochloride during simulated Y-site administration.
J Parenter Sci Technol 1993 ; 47: 35-39.
905 Czasopismo Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
934 Czasopismo Inagaki K, Kambara M, Mizuno M, Okuda J, Gill MA, Nishida M.
Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated Y-site administration.
Int J Pharm Compound 1998 ; 2: 318-321.
939 Czasopismo Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
958 Czasopismo Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M.
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion.
Ann Pharmacotherapy 1990 ; 24: 440-442.
1067 Czasopismo Zeidler C, Dettmering D, Schrammel W, Spieteller M.
Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers.
EJHP 1999 ; 5: 106-110.
1135 Czasopismo Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1232 Czasopismo Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1248 Czasopismo Walker SE, Bayliff CD.
Stability of ranitidine hydrochloride in total parenteral nutrient solution.
Am J Hosp Pharm 1985 ; 42: 590-592.
1315 Czasopismo Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410 Czasopismo Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Czasopismo Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1490 Czasopismo Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Czasopismo Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Czasopismo Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1703 Czasopismo Schuster F, Bernard R.
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Krankenhauspharmazie 1995 ; 16: 101-103.
1712 Czasopismo Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Czasopismo Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Czasopismo Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Czasopismo Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1757 Czasopismo Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P.
Determination of compatibility and stability of drugs used in palliative care.
J Clin Pharm Ther 1998 ; 23: 311-314.
1802 Czasopismo Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803 Czasopismo Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1847 Czasopismo Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G.
Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration.
J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1868 Czasopismo Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D.
Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange.
Nutr Clin Metab 2003 ; 17: 8-14.
1888 Czasopismo Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A.
Compatibility study of midazolam.
Ziekenhuisfarmacie 1986 ; 2: 45-48.
1900 Czasopismo Musami P, Stewart JT, Taylor EW.
Stability of zidovudine and ranitidine in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23°C±2°C) and 4°C in 50 ml polyvinylchloride bags up to 24 hours.
Int J Pharm Compound 2004 ; 8, 3: 236-239.
1925 Czasopismo Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Czasopismo Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Czasopismo Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
1987 Czasopismo Oh J, Gwak H, Moon H, Choi I.
Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations.
Am J Health-Syst Pharm 2005 ; 62: 289-291.
2002 Czasopismo Abanmy NO, Zaghloul IY, Radwan MA.
Compatibility of tramadol hydrochloride injection with selected drugs and solutions.
Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2090 Czasopismo Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2109 Czasopismo Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75.
2231 Czasopismo de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2262 Czasopismo Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Czasopismo Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2328 Laboratorium Sugammadex (Bridion®) – Résumé des caractéristiques du produits
Organon 2009
2355 Czasopismo Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M.
Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium nd cephalotin sodium during simulated Y-site administration.
Int J Pharm Compound 2000 ; 4, 2: 150-153.
3012 Czasopismo Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3152 Czasopismo Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216 Czasopismo Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Czasopismo Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Czasopismo Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332 Laboratorium Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3408 Czasopismo Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3526 Laboratorium Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3558 Czasopismo Rowe H, Riley J, Newby B.
Physical Compatibility of Ranitidine and Metoclopramide in 50-mL Minibags of Normal Saline.
Can J Hosp Pharm 2013 ; 66, 5: 332.
3571 Czasopismo Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3637 Laboratorium Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3766 Czasopismo Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Czasopismo Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3827 plakat Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 plakat Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 plakat So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3964 Czasopismo Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4055 Czasopismo Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4131 Czasopismo Fleming K, Donnelly R.
Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine.
Hosp Pharm 2019 ;54,1:32-36.
4145 Czasopismo Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Czasopismo Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4428 Czasopismo Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433 Czasopismo Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4470 Czasopismo Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P.
Continuous versus intermittent infusion of temocillin in intensive care unit patient.
Critical care 2005 ; 9(Suppl 1) P37
4528 Czasopismo Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Czasopismo Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.

  Mentions Légales